175 related articles for article (PubMed ID: 15490984)
1. Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis.
Yeung SM; Walker SE; Tailor SA; Awdishu L; Tobe S; Yassa T
Perit Dial Int; 2004; 24(5):447-53. PubMed ID: 15490984
[TBL] [Abstract][Full Text] [Related]
2. Steady-State Pharmacokinetics of Oral Ciprofloxacin in Continuous Cycling Peritoneal Dialysis Patients: Brief Report.
Lee C; Walker SAN; Palmay L; Walker SE; Tobe S; Simor A
Perit Dial Int; 2018; 38(1):73-76. PubMed ID: 29311199
[TBL] [Abstract][Full Text] [Related]
3. Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients.
Peerapornratana S; Chariyavilaskul P; Kanjanabuch T; Praditpornsilpa K; Eiam-Ong S; Katavetin P
Perit Dial Int; 2017; 37(2):218-224. PubMed ID: 27738089
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis.
Dahl NV; Foote EF; Searson KM; Fein JL; Kapoian T; Steward CA; Sherman RA
Ann Pharmacother; 1998 Dec; 32(12):1284-9. PubMed ID: 9876807
[TBL] [Abstract][Full Text] [Related]
5. Disposition of ceftazidime after intraperitoneal administration in adolescent patients receiving continuous cycling peritoneal dialysis.
Sisterhen LL; Stowe CD; Farrar HC; Blaszak CK; Blaszak RT
Am J Kidney Dis; 2006 Mar; 47(3):503-8. PubMed ID: 16490630
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal cefazolin and ceftazidime during short-dwell exchange in peritoneal dialysis patients with peritonitis.
Triyawatanyu P; Chariyavilaskul P; Phaisal W; Peerapornratana S; Kanjanabuch T; Praditpornsilpa K; Katavetin P
Perit Dial Int; 2020 Mar; 40(2):179-184. PubMed ID: 32063189
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.
Posthuma N; ter Wee PM; Donker AJ; Oe PL; Peers EM; Verbrugh HA
Perit Dial Int; 2000; 20 Suppl 2():S106-13. PubMed ID: 10911654
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin and ciprofloxacin: systemic antibiotic administration for peritoneal dialysis-associated peritonitis.
Goffin E; Herbiet L; Pouthier D; Pochet JM; Lafontaine JJ; Christophe JL; Gigi J; Vandercam B
Perit Dial Int; 2004; 24(5):433-9. PubMed ID: 15490982
[TBL] [Abstract][Full Text] [Related]
9. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD.
de Fijter CW; Biemond A; Oe LP; Moesker HL; Verhoef J; Donker AJ; Verbrugh HA
Adv Perit Dial; 1992; 8():18-21. PubMed ID: 1361781
[TBL] [Abstract][Full Text] [Related]
11. Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis be reduced on nocturnal intermittent peritoneal dialysis?
Cueto-Manzano AM; Rojas-Campos E; Martínez-Ramírez HR; Valera-González I; Medina M; Monteón F; Ruiz N; Becerra M; Palomeque MA; Cortés-Sanabria L
Perit Dial Int; 2006; 26(3):341-8. PubMed ID: 16722027
[TBL] [Abstract][Full Text] [Related]
12. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis.
Golper TA; Hartstein AI; Morthland VH; Christensen JM
Antimicrob Agents Chemother; 1987 Nov; 31(11):1787-90. PubMed ID: 3435126
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis.
Roberts DM; Ranganathan D; Wallis SC; Varghese JM; Kark A; Lipman J; Roberts JA
Perit Dial Int; 2016; 36(4):415-20. PubMed ID: 26764340
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis.
Elwell RJ; Frye RF; Bailie GR
Perit Dial Int; 2005; 25(4):380-6. PubMed ID: 16022096
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Manley HJ; Bailie GR; Asher RD; Eisele G; Frye RF
Perit Dial Int; 1999; 19(1):65-70. PubMed ID: 10201343
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis.
Zhu W; Fang X; Zheng J; Ke Y; He Q; Cui T; Chen B; Tian L
Ren Fail; 2023; 45(2):2285873. PubMed ID: 38044852
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of intermittent intraperitoneal ceftazidime.
Grabe DW; Bailie GR; Eisele G; Frye RF
Am J Kidney Dis; 1999 Jan; 33(1):111-7. PubMed ID: 9915275
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis.
Fleming LW; Moreland TA; Scott AC; Stewart WK; White LO
J Antimicrob Chemother; 1987 Apr; 19(4):493-503. PubMed ID: 3583969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
